PT  - JOURNAL ARTICLE
AU  - Yilong Wang
AU  - Shangrong Han
AU  - Haiqiang Qin
AU  - Huaguang Zheng
AU  - Bin Jiang
AU  - Yong Cao
AU  - Yuan Gao
AU  - Ling Guan
AU  - Qian Jia
AU  - Yong Jiang
AU  - Yuming Jiao
AU  - Shuya Li
AU  - Yapeng Li
AU  - Zixiao Li
AU  - Wei Liu
AU  - Xiaojuan Ru
AU  - Dongling Sun
AU  - Haixin Sun
AU  - Penglian Wang
AU  - Tingting Wang
AU  - Lixia Zong
AU  - Lei Guo
AU  - Xuewei Xie
AU  - Yuming Xu
AU  - Yuyuan Xu
AU  - Xiaomeng Yang
AU  - Yingying Yang
AU  - Mengyuan Zhou
AU  - Wenzhi Wang
ED  - ,
TI  - Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population
AID  - 10.1136/svn-2020-000385
DP  - 2020 Sep 01
TA  - Stroke and Vascular Neurology
PG  - 270--278
VI  - 5
IP  - 3
4099  - http://svn.bmj.com/content/5/3/270.short
4100  - http://svn.bmj.com/content/5/3/270.full
SO  - Stroke Vasc Neurol2020 Sep 01; 5
AB  - Aim Cerebrovascular disease is the leading cause of death and disability in China, causing a huge burden among patients and their families. Hence, stroke prevention is critical, especially in the high-risk population. Here, we present the evidence-based guideline suitable for the Chinese population.Methods Literature search of PubMed and Cochrane library (from January 1964 to June 2019) was done. After thorough discussion among the writing group members, recommendations were listed and summarised. This guideline was reviewed and discussed by the fellow writing committees of the Chinese Stroke Association’s Stroke.Results This evidence-based guideline was written in three parts: controlling the risk factors of stroke, utilisation of antiplatelet agents and assessing the risks of first-ever stroke. All recommendations were listed along with the recommending classes and levels of evidence.Conclusions This guideline provides recommendations for primary prevention of cerebrovascular disease among high-risk population in China. Controlling related risk factors, appropriately using antiplatelet agents, assessing the risk of developing first-ever stroke should help reduce the rate of cerebrovascular disease in China.